Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07349537 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 12 words Secondary endpoints: details revised at 1 of 7 entries · Site contacts updated at 2 of 9 sites Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 7 entries
    • Site contacts updated at 2 of 9 sites
  2. Trial sites expanded: 5 → 9 locationsv5
  3. Site contacts updated at 1 of 5 sitesv4
  4. Study sites: 4 to 5v3
  5. Study sites: 1 to 4v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Revolution Medicines, Inc.
16 trials monitored
See 1 trial at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 1 more disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Trial Details
NCT Number NCT07349537
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer +2 more
Enrollment 574 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov